Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
2 LEO Pharma Strengthens Global Leadership Team With Appointment of Jörg Möller as Executive Vice President, Global Research and Development
3 Roaming Charges: We Who Are About to Get Shot, Salute You
4 LEO Pharma announces positive results of Phase 2b dose-finding study with delgocitinib cream in adult patients with mild-to-severe chronic hand eczema (CHE)
5 LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab
6 LEO Pharma Announces U.S. Food and Drug Administration Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema
7 Wound-healing biomaterials activate immune system for stronger skin
8 LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020
9 Duke researchers unveil 'wound-healing' biomaterial for skin injuries
10 LEO Pharma Presents Data for Tralokinumab on Pooled Safety, S. aureus Colonization Reduction and Impact on Vaccine Response Rates at the 29th Annual European Academy of Dermatology and Venereology (EADV) Virtual Congress
11 Rare Skin Lymphoma Appears Treatable with Antibiotics
12 New Wound-Healing Biomaterials Reduce Scarring and Promote Tissue Regeneration
13 LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment
14 LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab, Demonstrating Safety and Sustained Improvements in Severity and Quality of Life Measures in Adults with Moderate-to-Severe Atopic Dermatitis
15 YAP-mediated mechanotransduction tunes the macrophage inflammatory response
16 Gel heals skin with less scarring and then vanishes
17 LEO Pharma Presents Results From Study of Twice-Weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for Topical Use in Long-Term Maintenance Treatment of Plaque Psoriasis
18 UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
19 Getting under the skin of psoriasis
20 Acute itching in eczema patients linked to environmental allergens
21 LEO Pharma strengthens global leadership team
22 Operation: Tango
23 LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab for the Treatment of Adults With Moderate-To-Severe Atopic Dermatitis
24 Atopic dermatitis symptoms, severity improve with tralokinumab plus corticosteroids
25 Research centres at the UCPH – University of Copenhagen
26 Antibiotics fight rare cancer and bacteria at the same time
27 World's first skin atlas to see the light of day
28 LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
29 Novel Drug Delivery Method Gets Under the Skin of Psoriasis
30 Natural killer cell immunotypes related to COVID-19 disease severity
31 Leukemia Research Foundation awards $1.3 million in grants
32 Genetic disposition protects immune system from aging
33 Glucocorticoid-Induced Skin Atrophy: The Old and the New | CCID
34 A molecular atlas of skin cells
35 Revving up immune system may help treat eczema – Washington University School of Medicine in St. Louis
36 Why antihistamines don't always ease chronic eczema itch
37 Endogenous DEL-1 restrains melanoma lung metastasis by limiting myeloid cell–associated lung inflammation
38 National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
39 Bimekizumab shows rapid, effective treatment of plaque psoriasis
40 Biosimilars Match Up With Originals for Skin Disorders
41 Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis
42 New promising antibodies against SARS-CoV-2: Combination of two molecules simultaneously attacks multiple sites on the surface of the virus
43 Type 1 diabetes, asthma may precede hidradenitis suppurativa diagnosis
44 Psoriasis Treatment Market Size Anticipated to Hit USD
45 Research Reveals How COVID-19 Can Kill Heart Muscle Cells, Interfere With Contraction
46 Ludwig Lausanne study charts the immune landscape of multiple brain cancers
47 Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nation | CLEP
48 Treating psoriasis inflammation can reduce cardiovascular risks
49 BIOS-SCOPE funding renewed
50 Global Psoriasis Drugs Market to Reach $53210.6 Million by 2030, says P&S Intelligence
51 Flexible, Personalized Care Needed for Psoriatic Disease During COVID-19 Pandemic
52 Diagnosed with cancer at age 8, Mateo Goldman needed something like a miracle. He got two
53 Study: About 10% of Baton Rouge adults had coronavirus by Aug. 2; see more 'very striking' findings
54 Monitoring of SARS‐CoV‐2 infection in mustelids
55 The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion
56 Autoimmunity plays a role in Parkinson's disease, study suggests: Scientists link immune cells to Parkinson's disease onset
57 Psoriasis Guidelines Focus on Treatment of Adults
58 LEO Pharma Further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine
59 IL-27 signaling activates skin cells to induce innate antiviral proteins and protects against Zika virus infection
60 LEO Pharma A/S Acquires Rights to Develop and Market brodalumab for Moderate-to-Severe Psoriasis Outside of Europe
61 High-resolution 3D imaging uncovers organ-specific vascular control of tissue aging
62 Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | NEJM
63 Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration
64 LEO Pharma to Acquire Global Dermatology Portfolio from Astellas
65 First-Ever Guidelines for Pediatric Psoriasis Bring Unique Concerns to Forefront
66 A nanomaterial path forward for COVID-19 vaccine development
67 Doctors studying why obesity may be tied to serious COVID-19
68 Land use impacts on parasitic infection: a cross-sectional epidemiological study on the role of irrigated agriculture in schistosome infection in a dammed landscape
69 Phosphodiesterase-4 Inhibition in Psoriasis
70 The Miseducation of America's Elites
71 DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
72 Damon Runyon Cancer Research Foundation awards nearly $4.3M to top young scientists
73 Polarization-sensitive stimulated Raman scattering imaging resolves amphotericin B orientation in Candida membrane
74 Natural Polyphyllins (I, II, D, VI, VII) Reverses Cancer Through Apopt | OTT
75 Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
76 Minocycline for Acne Changes Skin Microbiota | MedPage Today
77 COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
78 Helicobacter pylori Regulates the Apoptosis of Human Megakaryocyte Cel | OTT
79 JW Pharmaceutical signs global out-licensing agreement for their novel atopic dermatitis drug candidate, JW1601, with LEO Pharma, a global leader in medical dermatology
80 Pantera leo's family tree takes shape
81 Cloudy Swords
82 20 Supplements and Vitamins for Arthritis By Yvelette Stines
83 Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases
84 Parler CEO Says Service Dropped By “Every Vendor” And Could End His Business
85 UW studying 'COVID toes,' skin condition apparently linked to COVID-19
86 How Lemon Water Can Help Alleviate Arthritis Symptoms
87 The Center for the Study of Itch reviews what causes chronic itching and scratching
88 Revision ACL reconstruction with meniscal repair had less than 10% failure rate at 2-years
89 The biggest challenges to humans on long-term spaceflights
90 Many Medical Decision Tools Disadvantage Black Patients
91 LEO Pharma US Welcomes Judit H. Nyirady as Vice President of Medical Strategy & Scientific Affairs
92 Risankizumab may be superior to secukinumab in psoriasis treatment
93 LEO Pharma Strengthens Focus on Translational Medicine with the Appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor
94 LEO Pharma announces more than half of patients on Kyntheum® (brodalumab) maintain consistent levels of complete skin clearance for more than two years
95 Psoriasis Treatment Market to Exhibit 9.4% CAGR by 2026; Increasing Prescription Volume of Interleukin Inhibitors will Aid in Expansion of Market says Fortune Business Insights™
96 Coronaviruses do not readily induce cross-protective antibody responses
97 LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union
98 Latest Vaccine Development News
99 The BMJ Awards 2020 | BMJ
100 Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer | NEJM